Park Hotels & Resorts Inc. Common Stock vs Smith & Nephew plc — how do they compare? Park Hotels & Resorts Inc. Common Stock trades at $15.06 (market cap $3.05B), while Smith & Nephew plc trades at $28.24 (market cap $11.65B). The key difference: Smith & Nephew plc is far larger — about 3.8× Park Hotels & Resorts Inc. Common Stock's market cap, and Park Hotels & Resorts Inc. Common Stock pays the higher dividend (6.6%). Which is the better fit depends on your goals — on Pluang, investors hold Park Hotels & Resorts Inc. Common Stock for 0 Days and Smith & Nephew plc for 121 Days on average.
| PK | SNN | |
|---|---|---|
Market Cap | $3.05B | $11.65B |
Volume | 3,540,056 | 860,347 |
Sector | Real Estate | Health |
52-Week High | $16.17 | $37.17 |
52-Week Low | $9.84 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $6.89B | $14.68B |
Dividend Yield | 6.6% | 2.85% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $27.86, near a 52-week low, with a mixed technical signal. Revenue has grown from $5.2B in 2022 to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches like the EVOS PELVIC System highlight innovation, but the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show steady growth and a reasonable P/E of 18.95, weak sentiment and technical pressure near lows suggest limited near-term upside. Risks include execution challenges and competitive threats, but long-term investors may find value if operational improvements materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Park Hotels & Resorts Inc. is a US lodging REIT, spun off from Hilton Worldwide in 2017, that owns a portfolio of premium-branded hotels and resorts in major urban, resort, and convention markets.
Read more on PK →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →